The Year Medtech M&A Exploded – Medtech’s Largest 100 Players

Share

Welcome back to the Big 100, our annual look at the largest players in medical devices. Once again we’ve scoured the financial filings and annual reports of hundreds of companies dating back to the start of 2014.

The medtech landscape has changed significantly in the two years since our last edition of the Big 100, as mergers & acquisitions exploded. Some of the industry’s biggest names are off the table after a surge in megasized deals, and the activity extended on down the food chain to even the smallest players.

Inside you’ll find information on the world’s leading medical technology companies, ranked according to annual revenues. We also took a look at spending on research and development, the top employers in medtech, and an exciting roster of up-and-comers you’ll want to keep a close eye on.

The Big 100 also includes a look at notable moves in the corner office, as once again there was considerable churn. And be sure to check out our look at medtech’s hotspots.

Some notes on how we put this report together: For the Big 100 rankings, we looked at either calendar 2014 or the company’s most recently concluded fiscal year. We gleaned our information from our internal archives; corporate documents and public regulatory filings; and information from the companies’ websites.

To account for the diversified conglomerates that play in the medtech space, such as Johnson & Johnson, we did our best to isolate the revenues from their medical technology segments (e.g., J&J’s medical device & diagnostics business).

brad-p-medtech-big-100For companies based outside the U.S. that report their numbers in other currencies, we used the 2014 exchange rates established by the U.S. Federal Reserve to convert the figures into U.S. dollars. And finally, a pair of companies that would normally have made the list – Toshiba and Hanger Orthopedics – were left out because, as of press time, they had yet to file their annual reports for their most recent fiscal years.

How do you know your technology is disruptive enough to break conventional wisdom?

textadimage Stan Rowe knows a little something about bringing disruptive technology to market. The current Edwards Lifesciences CSO was in on the ground floor of two of medtech's most disruptive treatments, stents and transcatheter aortic valve replacement.

On December 12th, Rowe will sit down with MassDevice editor Brad Perriello for a long ranging discussion about the inside story on how these technologies came to market and what Rowe learned along the way.


Register now with the code "TAVR" and save 15% today.

Speak Your Mind

*